| Literature DB >> 28581512 |
Jun Lu1, Noel Byrne2, John Wang3, Gerard Bricogne4, Frank K Brown1, Harry R Chobanian5, Steven L Colletti5, Jerry Di Salvo3, Brande Thomas-Fowlkes3, Yan Guo5, Dawn L Hall2, Jennifer Hadix2, Nicholas B Hastings3, Jeffrey D Hermes2, Thu Ho2, Andrew D Howard6, Hubert Josien5, Maria Kornienko2, Kevin J Lumb2, Michael W Miller5, Sangita B Patel1, Barbara Pio5, Christopher W Plummer5, Bradley S Sherborne1, Payal Sheth3, Sarah Souza3, Srivanya Tummala2, Clemens Vonrhein4, Maria Webb3, Samantha J Allen2, Jennifer M Johnston1, Adam B Weinglass3, Sujata Sharma2, Stephen M Soisson1.
Abstract
Clinical studies indicate that partial agonists of the G-protein-coupled, free fatty acid receptor 1 GPR40 enhance glucose-dependent insulin secretion and represent a potential mechanism for the treatment of type 2 diabetes mellitus. Full allosteric agonists (AgoPAMs) of GPR40 bind to a site distinct from partial agonists and can provide additional efficacy. We report the 3.2-Å crystal structure of human GPR40 (hGPR40) in complex with both the partial agonist MK-8666 and an AgoPAM, which exposes a novel lipid-facing AgoPAM-binding pocket outside the transmembrane helical bundle. Comparison with an additional 2.2-Å structure of the hGPR40-MK-8666 binary complex reveals an induced-fit conformational coupling between the partial agonist and AgoPAM binding sites, involving rearrangements of the transmembrane helices 4 and 5 (TM4 and TM5) and transition of the intracellular loop 2 (ICL2) into a short helix. These conformational changes likely prime GPR40 to a more active-like state and explain the binding cooperativity between these ligands.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28581512 DOI: 10.1038/nsmb.3417
Source DB: PubMed Journal: Nat Struct Mol Biol ISSN: 1545-9985 Impact factor: 15.369